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Commercial pigs have been routinely injected with multiple vaccines that are either administered 
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KNB-E2 vaccination. Pigs co-administered with JXA1-R vaccine and pigs vaccinated with JXA1-R two 
weeks before KNB-E2 vaccination had slightly lower CSFV-specific antibodies than pigs vaccinated with 
KNB-E2 alone at 3 weeks post KNB-E2 vaccination. However, both groups of JXA1-R/KNB-E2 vaccinated 
pigs were amply protected from CSF clinical symptoms upon challenge. The immunological responses 
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The Impact of Attenuated Porcine 
Reproductive and Respiratory Syndrome 
(PRRS) Vaccine on the Efficacy of Subunit 
Classical Swine Fever Vaccine1
Rachel Madera,2 Lihua Wang,2 Ada Giselle Cino-Ozuna,3 and Jishu Shi2
Summary
Commercial pigs have been routinely injected with multiple vaccines that are either 
administered separately or co-administered at the same time for convenience, and 
to minimize pig stress. However, viruses, including attenuated and modified live 
virus (MLV) vaccines, can modulate host immune responses that could potentially 
impact the efficacy of co-administered vaccines. Here we report the effects of pre- and 
co-administered Chinese highly pathogenic porcine reproductive and respiratory 
syndrome (PRRS) virus MLV, JXA1-R, on the efficacy of an emulsion-based classical 
swine fever virus (CSFV) subunit vaccine, KNB-E2. Immune responses to the CSFV 
and JXA1-R vaccines were evaluated by testing CSFV-specific and PRRSV-specific sera 
antibodies and then challenged with CSFV at 4 weeks post KNB-E2 vaccination. Pigs 
co-administered with JXA1-R vaccine and pigs vaccinated with JXA1-R two weeks 
before KNB-E2 vaccination had slightly lower CSFV-specific antibodies than pigs 
vaccinated with KNB-E2 alone at 3 weeks post KNB-E2 vaccination. However, both 
groups of JXA1-R/KNB-E2 vaccinated pigs were amply protected from CSF clinical 
symptoms upon challenge. The immunological responses affected by various multiple 
vaccination combinations in swine would be an interesting aspect for future investiga-
tions. 
Introduction
Pigs are routinely immunized with multiple vaccines to prevent or control infectious 
diseases. To save time, labor, and stress of handling pigs multiple times, vaccine compa-
nies supply single-dose, multiple-way vaccines comprised of both live (attenuated or 
modified) and non-live (inactivated, killed or subunit) vaccines. However, live viral 
vaccines could modulate the host immune responses and potentially affect the efficacy 
of co-administered vaccines.
1 This research is supported by awards from the National Bio and Agro-Defense Facility Transition 
Fund, the USDA National Institute of Food and Agriculture, Hatch-Multistate project 1021491, USDA 
ARS Non-Assistance Cooperative Agreements (58-8064-8-011, 58-8064-9-007, 58-3020-9-020, and 
59-0208-9-222), and National Pork Board Grant #18-059.
2 Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University.
3 Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University.
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Classical swine fever (CSF) or hog cholera is a highly contagious swine viral disease that 
causes severe economic losses to the swine industry worldwide. The etiological agent 
CSF virus (CSFV), is a positive-sense, single-stranded RNA virus that belongs to the 
Flaviviridae family under Pestivirus genus. In CSF-endemic countries, pigs are routinely 
vaccinated with CSFV vaccines together with other pig vaccines such as PRRS. 
The PRRS continues to be one of the most widespread and economically devastating 
diseases in the swine industry. The causative agent PRRSV is a relatively small, positive-
sense, single-stranded RNA virus with observed high-mutation rate due to the nature of 
its RNA genome. The highly contagious PRRS virus significantly inhibits host immune 
responses during the early stage of infection.4 A PRRS infection also leads to signifi-
cant thymus atrophy and injuries to tonsil and lymph nodes, and therefore, further 
weakening the immune response. Moreover, PRRSV infection prior to CSFV vaccina-
tion significantly suppresses the CSFV-specific antibody responses, and this immune 
suppression has been previously reported in PRRS MLV vaccine (Ingelvac).5
In the present study, we evaluated the effect of an attenuated Chinese highly pathogenic 
PRRS vaccine, JXA1-R,6 on the efficacy of CSFV subunit vaccine, KNB-E2,7,8 in terms 
of schedule of vaccination. 
Procedures
Cells, Viruses, Vaccines, and Vaccination
Simian kidney epithelial cells (MARC-145), swine testicle (ST) cells, the Chinese 
highly pathogenic PRRS modified live vaccine (HP-PRRS MLV), JXA1-R, Classical 
swine fever virus isolate Alfort (HCV Alfort C-718 28), and the CSFV E2 sub-unit 
vaccine, KNB-E2 were prepared as we described previously.6,7,8 All vaccinated pigs 
were immunized once intramuscularly in the neck area with 2 mL of KNB-E2 and/or 
JXA1-R. A group of positive control pigs were vaccinated with KNB-E2 only. The non-
vaccinated, nonchallenged (-/-); and non-vaccinated, CSFV-challenged (-/+) negative 
control pig groups were injected intramuscularly with 2 mL of PBS.
4 Subramaniam, S., Kwon, B., Beura, L. K., Kuszynski, C. A., Pattnaik, A. K., and Osorio, F. A. 2010. 
Porcine reproductive and respiratory syndrome virus non-structural protein 1 suppresses tumor necrosis 
factor-alpha promoter activation by inhibiting NF-κB and Sp1. Virology, 406, 270–279. https://doi.
org/10.1016/j.virol.2010.07.016.
5 Wang, X., Mu, G., Dang, R., and Yang, Z. 2016. Up-regulation of IL-10 upon PRRSV vaccination 
impacts on the immune response against CSFV. Veterinary Microbiology, 197, 68–71. https://doi.
org/10.1016/j.vetmic.2016.11.007.
6 Galliher-Beckley, Amy, Li, X., Bates, J. T., Madera, R., Waters, A., Nietfeld, J., Henningson, J., He, D., 
Feng, W., Chen, R., and Shi, J. 2015. Pigs immunized with Chinese highly pathogenic PRRS virus modi-
fied live vaccine are protected from challenge with North American PRRSV strain NADC-20. Vaccine, 
33(30), 3518–3525. https://doi.org/10.1016/j.vaccine.2015.05.058.
7 Madera, R., Gong, W., Wang, L., Burakova, Y., Lleellish, K., Galliher-Beckley, A., Nietfeld, J., 
Henningson, J., Jia, K., Li, P., Bai, J., Schlup, J., McVey, S., Tu, C., and Shi, J. 2016. Pigs immunized with 
a novel E2 subunit vaccine are protected from subgenotype heterologous classical swine fever virus chal-
lenge. BMC Veterinary Research, 12(1), 1–10. https://doi.org/10.1186/s12917-016-0823-4.
8 Madera, R., Wang, L., Gong, W., Burakova, Y., Buist, S., Nietfeld, J., Henningson, J., Cino-Ozuna, A., 
Tu, C., and Shi, J. 2018. Toward the development of a one-dose classical swine fever subunit vaccine: 
antigen titration, immunity onset, and duration of immunity. Journal of Veterinary Science, 19(3), 
393–405.
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Animals and CSFV Challenge Study
Conventional Large White-Duroc crossbred weaned specific-pathogen free female 
piglets (3 weeks of age) were purchased from a commercial vendor. The pigs were fed 
with standard commercial diet and kept under laboratory biosafety level II (BSL2) 
conditions at the Large Animal Research Center (LARC) during the vaccination 
phase; and under laboratory biosafety level III Agriculture (BSL3-Ag) conditions at 
the Biosecurity Research Institute (BRI) during the CSF challenge phase. Both facili-
ties are at Kansas State University. Animal care and use protocols were approved by 
the Kansas State University Institutional Animal Care and Use Committee (IACUC 
No. 3892). To test the efficacy of KNB-E2 in pigs vaccinated with JXA1-R, 25 pigs 
were randomly allotted into five groups: (1) non-vaccinated, non-challenged pigs (-/-); 
(2) non-vaccinated, CSFV-challenged (-/+) pigs; (3) pigs that were vaccinated with 
JXA1-R and then vaccinated with KNB-E2 after two weeks (pre JXA1-R + KNB-E2); 
(4) pigs that were vaccinated with JXA1-R and KNB-E2 at the same time (JXA1-R + 
KNB-E2 co-vax); and (5) pigs that were single vaccinated with KNB-E2 (KNB-E2 ctrl). 
All KNB-E2 vaccinations were performed on the same day, at two weeks post JXA1-R 
vaccination of pre JXA1-R + KNB-E2 pigs. Four weeks after KNB-E2 vaccination, the 
pigs were challenged with 1 × 105 TCID50 CSFV isolate Alfort (1 mL, intramuscularly). 
Pigs were monitored daily for clinical signs and rectal temperatures after CSFV chal-
lenge. Blood was collected weekly during the vaccination phase and every 3 days during 
the challenge phase. End of study was at 15 days post challenge (DPC). 
Serum Isolation, ELISAs, and CSFV Detection, Virus Neutralizing Titer 
in Serum, and Statistical Analysis
Serum was separated from clotted blood and preserved at -20°C until used for assays. 
Serum isolation, ELISAs, and CSFV detection, virus neutralizing titer in serum, and 
statistical analysis were performed as we described previously.4
Results and Discussion
JXA1-R and KNB-E2 Double Vaccinated Pigs Have Lower CSFV-
Specific Antibodies than Single Vaccinated KNB-E2 Pigs
To determine whether vaccination with JXA1-R could affect the efficacy of KNB-E2 
CSF sub-unit vaccine, two groups of pigs were immunized with both JXA1-R and 
KNB-E2 at different time points (pre JXA1-R + KNB-E2 and JXA1-R + KNB-E2 
co-vax) and then challenged with CSFV 4 weeks post KNB-E2 vaccination. No marked 
differences in the CSFV-specific antibodies were observed between pre JXA1-R + 
KNB-E2 and JXA1-R + KNB-E2 co-vax pig groups (Figure 1). Interestingly, the CSFV-
specific antibodies observed in JXA1-R and KNB-E2 double vaccinated pigs appear to 
be lower (difference not statistically significant) than single vaccinated KNB-E2 ctrl 
pigs at 4 weeks post KNB-E2 vaccination. The observed difference in CSFV-specific 
antibodies, although minimal, possibly indicate an effect of JXA1-R vaccination.
JXA1-R and KNB-E2 Double Vaccinated Pigs Were Protected Against CSF
Upon CSF challenge, all single and double vaccinated pigs did not exhibit CSF clinical 
symptoms. These single and double vaccinated pigs steadily gained weight throughout 
the 15-day CSFV challenge period (Figure 2). In contrast, weight loss was observed in 
the negative (-/+) CSF-challenged control group starting at 6 DPC. Elevated tempera-
Kansas State University Agricultural Experiment Station and Cooperative Extension Service
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tures were also observed in this control group (Figure 3). Although slightly lower 
CSFV-specific antibodies were observed in double vaccinated pigs during the vaccina-
tion phase, the continued body weight gain, and the absence of elevated temperatures in 
single and double vaccinated pigs during the challenge phase indicate sufficient protec-
tion by KNB-E2 vaccination against CSF disease. 
To further determine whether the timing of JXA1-R vaccination influenced the 
induced CSF-specific immune responses by KNB-E2, CSFV quantification was deter-
mined by real-time RT-PCR in which positive results were considered for threshold 
cycle values (Ct) equal to or less than 40. Samples in which fluorescence was undetect-
able were considered negative. CSF was detected starting at 3 DPC (Figure 4). The 
pre JXA1-R + KNB-E2 pigs also tested positive at 3 DPC like the (-/+) control pigs 
but fluorescence detected did not go as high as the (-/+) control pigs. However, pre 
JXA1-R + KNB-E2 pigs tested CSF negative at 9 DPC and again tested positive at 12 
DPC which suggests the persistence of CSF virus throughout the challenge period in 
this pig group (Figure 4). In contrast, the JXA1-R + KNB-E2 co-vax and KNB-E2 ctrl 
pig groups transiently had little or no virus detected at 6 DPC and were quickly cleared 
afterwards (Figure 4). Of note, CSFV was not detected in the KNB-E2 ctrl pig group by 
9 DPC. This finding suggests that the observed decrease in body weight gain (Figure 2) 
and slightly elevated temperature (Figure 3) in KNB-E2 ctrl pig group towards the end 
of the study were due to unrelated non-CSFV health issues. 
To determine the amount of virus neutralizing antibody (VNA) titers present in 
the blood, pig sera were incubated with CSFV for an hour, cultured in ST cells for 
72 hours, and virus infection was visualized by immunofluorescence staining. Low levels 
of anti-CSFV neutralizing titers were detected in all vaccinated groups before challenge 
with the notably lower VNA titers in the pre JXA1-R + KNB-E2 pig group. However, 
by the end of the study (15 DPC) all the vaccinated pigs groups developed very high 
VNA titers (data not shown). Interestingly, all the (-/+) control pigs developed low 
levels of VNA titers by 15 DPC. However, the VNA titers of the (-/+) control pigs 
were still significantly lower compared with all the vaccinated pigs. Taken together, our 
data suggest that KNB-E2 remain efficacious in pigs that are pre-vaccinated or co-vacci-
nated with the PRRS MLV vaccine JXA1-R. However, the subtle differences observed 
in the double vaccinated pigs could indicate an unaccounted effect of modified live 
virus vaccination.
Our results show the effects of Chinese highly pathogenic PRRS vaccine, JXA1-R, on 
the efficacy of CSFV subunit vaccine, KNB-E2, in which the effects were determined 
by CSFV Alfort challenge. All JXA1-R and KNB-E2 double vaccinated pigs were 
protected against CSF clinical symptoms. These pigs displayed continued body weight 
gain, no CSF clinical symptoms, and the absence of high fever after CSFV infection. In 
contrast to (-/+) unvaccinated CSF challenged pigs, all JXA1-R and KNB-E2 double 
vaccinated pigs exhibited no or low levels of CSF viremia. The JXA1-R + KNB-E2 
co-vax had lower CSFV E2-specific and neutralizing antibodies but developed very 
high antibody levels during the challenge phase. The pre JXA1-R + KNB-E2 pigs had 
displayed higher PRRS-specific antibodies at 2 weeks post JXA1-R vaccination than 
JXA1-R + KNB-E2 co-vax pigs and lower CSF-specific antibodies at 4 weeks post 
KNB-E2 vaccination. Although the retained efficacy displayed by the KNB-E2 vaccine 
Kansas State University Agricultural Experiment Station and Cooperative Extension Service
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illustrates the minimal impact of JXA1-R pre-vaccination and co-vaccination, notable 
differences were observed between single and double vaccination. 
Taking into consideration that infection with various PRRSV strains could inhibit the 
replication and efficacy of C-strain CSF MLV9 and that KNB-E2 vaccinated pigs are 
protected against CSF challenge even with prior or co-PRRSV vaccination, the use of 
KNB-E2 CSF vaccine could be a potential alternative to C-strain CSF MLV vaccina-
tion. This subunit vaccine could confer protection against CSF in a single dose vaccina-
tion at two weeks post vaccination.4,5 It induces strong immune responses against CSFV 
without the untoward effects of immune deregulation induced by virus-based vaccines. 
The effects of pre- and co-vaccination of JXA1-R and KNB-E2 were not tested against 
PRRSV challenge. Results indicate slightly lower PRRS-specific antibodies at 2 weeks 
post JXA1-R co-vaccination in comparison with JXA1-R pre-vaccination (data not 
shown). However, the observed S/P values (>0.4) on these pigs show successful sero-
conversion and this is an indication of elicited immunity against PRRSV.
We have demonstrated JXA1-R PRRS vaccine to be safe for use in multiple-dose 
vaccination with little or no effect on the efficacy of KNB-E2 CSF subunit vaccine. 
The Chinese highly pathogenic PRRS virus MLV, JXA1-R appears to have minimal 
immune suppression and no effects on subunit KNB-E2 CSF vaccine efficacy. Although 
no drastic differences were observed between pre-vaccination and co-vaccination of the 
vaccines, the results, nevertheless, indicate that the effect of multiple vaccinations in pig 
immunization schedules needs to be further addressed. 
9 Chen, D., Liu, X., Xu, S., Chen, D., Zhou, L., Ge, X., Han, J., Guo, X., and Yang, H. 2019. TNF-α 
induced by porcine reproductive and respiratory syndrome virus inhibits the replication of clas-
sical swine fever virus C-strain. Veterinary Microbiology, 234, 25–33. https://doi.org/10.1016/j.
vetmic.2019.05.007.
Kansas State University Agricultural Experiment Station and Cooperative Extension Service
6
Swine Day 2020
Figure 1. Anti-CSF antibody responses of JXA1-R and KNB-E2 pre- and co-vaccinated 
pigs post vaccination. Pigs pre-vaccinated with JXA1-R (pre JXA1-R + KNB-E2) and 
pigs vaccinated with JXA1-R and KNB-E2 at the same time (JXA1-R + KNB-E2 co-vax) 
displayed slightly lower anti-E2 CSF antibodies compared with pigs that were vaccinated 
only with the classical swine fever sub-unit vaccine (KNB-E2 ctrl). ELISA plates coated 
with 62 ng/mL E2 antigen and serum samples diluted 1:1,000. Data are group mean ± 
SEM (n = 5) absorbance determined by E2-specific ELISA.
Figure 2. Body weight gain post CSF challenge of JXA1-R and KNB-E2 pre- and co-vacci-
nated pigs. All experimental pig groups displayed continued weight gain post CSF chal-
lenge. The observed weight loss at 15 DPC in the pigs vaccinated with KNB-E2 only 
vaccine (KNB-E2 ctrl) was not CSF-related. Data are group mean ± SEM (n = 5) fold body 
weight gain calculated by considering 0 DPC pig weight as 1.
Kansas State University Agricultural Experiment Station and Cooperative Extension Service
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Figure 3. Body temperature of JXA1-R and KNB-E2 pre- and co-vaccinated pigs post 
CSFV challenge. Pigs pre-vaccinated with JXA1-R (pre JXA1-R + KNB-E2), pigs vacci-
nated with JXA1-R and KNB-E2 at the same time (JXA1-R + KNB-E2 co-vax) and pigs 
vaccinated with KNB-E2 only (KNB-E2 ctrl) did not develop clinical fever after challenge 
with CSF virus. Data are group mean ± SEM (n = 5) temperature (°Celsius).
Figure 4. Viremia of JXA1-R and KNB-E2 pre- and co-vaccinated pigs post CSFV chal-
lenge. Pigs pre-vaccinated with JXA1-R (pre JXA1-R + KNB-E2), pigs vaccinated with 
JXA1-R and KNB-E2 at the same time (JXA1-R + KNB-E2 co-vax) and pigs vaccinated 
with KNB-E2 only (KNB-E2 ctrl) did not develop high levels of CSFV viremia. Samples 
with real-time RT-PCR threshold cycle (Ct) values equal or less than 40 were considered 
positive for CSFV. Data are group mean ± SEM (n = 5) Ct values.
